SetPoint Raises $140M to Support Neuromod RA Therapy Commercialization

SetPoint Medical has raised $140 million in private financing, which includes $25 million in the second tranche of its Series C financing, and $115 million in its Series D financing, co-led by Elevage Medical Technologies and Ally Bridge Group.

The company said these proceeds will support commercialization of the SetPoint system, a neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis (RA). It will also be used to advance the company’s pipeline in other autoimmune conditions.

In conjunction with the Series D, Josh Makower, MD joined the company’s board of directors as a representative of Elevage Medical Technologies, along with Kevin Reilly, Managing Director and Head of MedTech investments at Ally Bridge Group.

SetPoint also made two new executive appointments. Erik Styacich, former VP of Sales for neuromodulation company Valencia Technologies, joined as VP of Sales, and Spencer Bailey joined as VP of Market Access & Reimbursement, after holding several similar leadership roles at other neuromodulation companies, including MicroTransponder.

The company’s neuroimmune platform won FDA approval for RA late last month.

“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the SetPoint System in select U.S. markets this year, with broader national expansion in 2026,” said Murthy V. Simhambhatla, Ph.D., CEO of SetPoint Medical. “We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”